Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15900274 | 0.81 | BACE1 (0.35) | GRM4 | |
| SCHEMBL15900267 | 0.78 | DAO (0.34) | GRM4 | |
| SCHEMBL15900275 | 0.77 | BACE1 (0.37) | KDM4E | |
| SCHEMBL17892 | 0.76 | — | — | |
| SCHEMBL16461250 | 0.75 | CYP11B1 (0.35) | — | |
| SCHEMBL22326641 | 0.75 | CCR1 (0.48) | CCR1CCR5CCR8SLC40A1KDM4E | |
| SCHEMBL28961824 | 0.75 | CCR1 (0.43) | CCR1CCR5CCR8KDM4EPSMD14 | |
| SCHEMBL15900420 | 0.74 | BACE1 (0.37) | — | |
| SCHEMBL18260489 | 0.73 | CCR1 (0.42) | CCR1CCR5CCR8SLC40A1KDM4E | |
| SCHEMBL16462069 | 0.72 | AKT1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9611261-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160280695-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-9309263-B2 | Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof | AMGEN INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9296734-B2 | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150252011-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
| US-9096615-B2 | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9085576-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150038497-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC. | 2015-02-05 | — | — | US | disclosed |
| US-20140275058-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140249104-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
| US-20140213581-A1 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280695-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 3730/4885CCR5 3261/4885CCR8 3143/4885 |
| US-20140275058-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 3730/4885CCR5 3261/4885CCR8 3143/4885 |
| US-20140249104-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 4463/4885CCR5 3263/4885CCR8 4318/4885 |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 4358/4885CCR5 3328/4885CCR8 3775/4885 |
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CCR1 4618/4885CCR5 4327/4885CCR8 4189/4885 |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 4788/4885CCR5 3938/4885CCR8 4708/4885 |
| US-20150038497-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CCR1 4618/4885CCR5 4327/4885CCR8 4189/4885 |
| US-20150252011-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 3730/4885CCR5 3261/4885CCR8 3143/4885 |
| US-20140213581-A1 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CCR1 4753/4885CCR5 4129/4885CCR8 4424/4885 |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | CCR1 4788/4885CCR5 3938/4885CCR8 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.